Topic
Regenerative Medicine
17 published works
Regulatory Oversight
Iowa AG Obtains Court Injunction and Civil Penalties Against Stem Cell Company in Four-Day Trial
By Troutman Pepper Locke State Attorneys General Team
After a four-day trial, Iowa Attorney General (AG) Brenna Bird obtained a ruling and judgment against Omaha-based stem cell businesses and its owner/CEO for deceptively marketing "regenerative medicine" stem cell…
Big Molecule Watch
FDA Designates Intellia’s Nexiguran Ziclumeran (nex-z) as a Regenerative Medicine Advanced Therapy
By Yoko Bian
On November 25, 2024, Intellia Therapeutics announced that its CRISPR-based therapy, nexiguran ziclumeran (nex-z, NTLA-2001), received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treatment of hereditary transthyretin…
Napoli Shkolnik Blog
Most Regenerative Medicine Therapies on the Market Are Not FDA Approved
Dozens of spine surgery patients at NewYork-Presbyterian/Weill Cornell Medical Center were treated with a product that was not approved for use in such procedures, The New York Times reported. The…
Health Care and Life Sciences
FDA Cracking Down on Unapproved HCT/Ps with Fourth Untitled Letter of 2023
By Dominick DiSabatino, Cortney Inman
On May 22, 2023, the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) issued an untitled letter to AT Venture Center for Global…
Health Care and Life Sciences
In Response to COVID-19, FDA Extends Enforcement Discretion for HCT/Ps Requiring Pre-Market Review
By Amy K. Dow
On July 20, 2020, the United States Food and Drug Administration (FDA) announced a six-month extension of its enforcement discretion policy for certain regenerative medicine products requiring pre-market review due…
ZP Perspectives
FDA Enforcement Update: Recent Changes in Policing Stem Cell Products
As the COVID-19 pandemic continues, so have regulatory actions by the U.S. Food and Drug Administration (FDA) affecting the regenerative medicine industry. This includes the issuance of agency demand letters…
Health Care and Life Sciences
FDA Finalizes Two Guidance Documents Regarding Regenerative Medicine Therapies
On February 15, 2019, the U.S. Food and Drug Administration (“FDA”) finalized two guidance documents regarding regenerative medicine therapies (see FDA’s announcement here). This development comes nearly 14 months after…
Elder Law Prof Blog
Regenerative Medicine: The FDA
By rmorgan
Stem Cells! The New England Journal of Medicine published an article on regenerative medicine. Rejuvenating Regenerative Medicine Regulation explains FDA action regarding the regulation of regenerative medicine. The Food and Drug…
BioLoquitur
No Longer the Stuff of Science Fiction: The FDA’s New Policy Approach to Regenerative Medicine Products
The ability to facilitate the regeneration of parts of the human body is “no longer the stuff of science fiction” according to FDA Commissioner Scott Gottlieb.[i] According to Commissioner Gottlieb, the…
Focus on Regulation
FDA Clarifies and Expands Eligibility for RMAT Designation for Gene Therapies
By David Horowitz, Mike Druckman, David Fox, Susan Lee
On November 16, in the context of announcing a comprehensive regenerative medicine policy framework (discussed here), FDA released a draft guidance document that describes the expedited programs available for the…